$PHIO
Phio Pharmaceuticals Corp

2014 Q1 Form 10-K Financial Statement

#000119312514121519 Filed on March 28, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q4 2013
Revenue $29.00K $30.00K $399.0K
YoY Change -45.28% -25.0% 311.34%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $840.0K $1.110M $3.700M
YoY Change -93.5% 79.03% 41.22%
% of Gross Profit
Research & Development $1.476M $1.440M $17.65M
YoY Change -89.28% 26.32% 68.89%
% of Gross Profit
Depreciation & Amortization $22.00K $20.00K $99.00K
YoY Change -15.38% -33.33% -32.65%
% of Gross Profit
Operating Expenses $2.319M $2.550M $21.35M
YoY Change -83.95% 45.71% 63.31%
Operating Profit -$2.290M -$20.95M
YoY Change -84.09% 61.46%
Interest Expense $6.000K $10.00K $24.00K
YoY Change -180.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change -100.0%
Pretax Income -$2.280M -$2.510M -$20.93M
YoY Change -84.17% 46.78% 62.46%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.284M -$2.510M -$20.93M
YoY Change -84.14% 46.78% 62.46%
Net Earnings / Revenue -7875.86% -8366.67% -5244.36%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.761B -$1.751B -$15.83B
COMMON SHARES
Basic Shares Outstanding 13.37M shares 11.68M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2013 Q4 2013
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.01M $14.39M $14.39M
YoY Change -38.85% 180.51% 180.51%
Cash & Equivalents $9.010M $11.39M $11.39M
Short-Term Investments $3.000M $3.000M $3.000M
Other Short-Term Assets $280.0K $350.0K $350.0K
YoY Change 86.67% 34.62% 34.62%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.29M $14.74M $14.74M
YoY Change -37.94% 173.42% 173.47%
LONG-TERM ASSETS
Property, Plant & Equipment $155.0K $177.0K $180.0K
YoY Change -9.88% -10.61% -10.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.00K $18.00K $20.00K
YoY Change
Total Long-Term Assets $173.0K $195.0K $200.0K
YoY Change -0.57% -2.5% 0.0%
TOTAL ASSETS
Total Short-Term Assets $12.29M $14.74M $14.74M
Total Long-Term Assets $173.0K $195.0K $200.0K
Total Assets $12.46M $14.94M $14.94M
YoY Change -37.62% 167.13% 167.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $277.0K $163.0K $160.0K
YoY Change -24.32% -60.82% -61.9%
Accrued Expenses $1.024M $1.795M $1.800M
YoY Change -9.06% 134.03% 133.77%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $1.390M $2.076M $2.080M
YoY Change -29.01% 23.65% 23.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.390M $2.076M $2.080M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.390M $2.076M $2.080M
YoY Change -29.01% 21.69% 21.64%
SHAREHOLDERS EQUITY
Retained Earnings -$38.08M
YoY Change -321.96%
Common Stock $1.000K $1.000K
YoY Change -96.88% -93.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.219M $4.942M $12.86M
YoY Change
Total Liabilities & Shareholders Equity $12.46M $14.94M $14.94M
YoY Change -37.62% 167.13% 167.26%

Cashflow Statement

Concept 2014 Q1 2013 Q4 2013
OPERATING ACTIVITIES
Net Income -$2.284M -$2.510M -$20.93M
YoY Change -84.14% 46.78% 62.46%
Depreciation, Depletion And Amortization $22.00K $20.00K $99.00K
YoY Change -15.38% -33.33% -32.65%
Cash From Operating Activities -$2.380M -$1.400M -$6.311M
YoY Change 110.99% 21.74% 24.67%
INVESTING ACTIVITIES
Capital Expenditures -$70.00K $78.00K
YoY Change 600.0% 420.0%
Acquisitions
YoY Change
Other Investing Activities $5.980M $18.00K
YoY Change 59700.0% 800.0%
Cash From Investing Activities $5.920M -$3.093M
YoY Change 59100.0% -19431.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $15.65M
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.00K 15.67M
YoY Change 62.02%
NET CHANGE
Cash From Operating Activities -2.380M -1.400M -6.311M
Cash From Investing Activities 5.920M -3.093M
Cash From Financing Activities 30.00K 15.67M
Net Change In Cash -2.380M 4.550M 6.263M
YoY Change -116.4% -499.12% 35.45%
FREE CASH FLOW
Cash From Operating Activities -$2.380M -$1.400M -$6.311M
Capital Expenditures -$70.00K $78.00K
Free Cash Flow -$2.380M -$1.330M -$6.389M
YoY Change 110.99% 16.67% 25.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
741000
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
2430000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
shares
CY2006Q4 us-gaap Stockholders Equity
StockholdersEquity
2000
CY2006Q4 rxii Predecessor Stockholders Equity
PredecessorStockholdersEquity
-268000
CY2007Q4 us-gaap Stockholders Equity
StockholdersEquity
10823000
CY2008Q4 us-gaap Stockholders Equity
StockholdersEquity
8968000
CY2006Q2 us-gaap Stockholders Equity
StockholdersEquity
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
4.35
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13373239 shares
CY2013Q2 dei Entity Public Float
EntityPublicFloat
46177173
CY2002Q4 rxii Predecessor Stockholders Equity
PredecessorStockholdersEquity
CY2003Q4 rxii Predecessor Stockholders Equity
PredecessorStockholdersEquity
-89000
CY2004Q4 rxii Predecessor Stockholders Equity
PredecessorStockholdersEquity
-968000
CY2005Q4 rxii Predecessor Stockholders Equity
PredecessorStockholdersEquity
-450000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-587000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
503000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5289007 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5289007 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.00
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2128266 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
767000
CY2012Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
5000
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
585000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11317000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
416000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
107000
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3501000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1679000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
403000
CY2012Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
17000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-5840000
CY2012Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
614000
CY2013Q1 rxii Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
16400000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
163000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
190000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
117000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14626000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2076000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
30000
CY2013Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
153000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
627000
CY2013Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
26000
CY2013Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
150000
CY2012Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3054000
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
27000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
491000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5592000
CY2012Q4 us-gaap Liabilities
Liabilities
1706000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
CY2012Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
57000
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
5392000
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
282000
CY2012Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
26000
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3501000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
53000
CY2012Q4 us-gaap Assets
Assets
5592000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5127000
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
17157000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
212000
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
105000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
198000
CY2012Q4 rxii Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
104000
CY2012Q4 rxii Clinical Development Expenses Current
ClinicalDevelopmentExpensesCurrent
153000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11788045 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1023597 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11788045 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.47
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2556269 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2443731 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.26
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1500000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1795000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
118000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
632000
CY2013Q4 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
153000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
183000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
40969000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
4942000
CY2013Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
0
CY2013Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
575000
CY2013Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
120000
CY2013Q4 us-gaap Contractual Obligation
ContractualObligation
1687000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
118000
CY2013Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
503000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14938000
CY2013Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
153000
CY2013Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
0
CY2013Q4 us-gaap Liabilities
Liabilities
2076000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
119000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
110000
CY2013Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
6864000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
146000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
14743000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
861000
CY2013Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
18000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6590000
CY2013Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
26000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
14626000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2013Q4 us-gaap Assets
Assets
14938000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11390000
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
3000000
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
234000
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
38082000
CY2013Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
30300000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
303000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
555000
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3627000
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
165000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
177000
CY2013Q4 rxii Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
130000
CY2013Q4 rxii Clinical Development Expenses Current
ClinicalDevelopmentExpensesCurrent
665000
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3765230 shares
CY2013Q1 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
1666666 shares
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15700000
CY2013Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
Board of Directors of the Company approved a 1-for-30 reverse stock split of the Company's outstanding common stock
CY2013Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.033 pure
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M23D
rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
2000
CY2003 us-gaap Net Income Loss
NetIncomeLoss
-89000
CY2005 us-gaap Net Income Loss
NetIncomeLoss
-2209000
CY2005 rxii Net Transactions With Parent
NetTransactionsWithParent
2727000
CY2006 us-gaap Net Income Loss
NetIncomeLoss
-2405000
CY2006 rxii Net Transactions With Parent
NetTransactionsWithParent
2587000
CY2007 us-gaap Net Income Loss
NetIncomeLoss
-10990000
CY2007 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1814000
CY2007 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
4318000
CY2007 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
15679000
CY2009 us-gaap Net Income Loss
NetIncomeLoss
-18387000
CY2009 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4202000
CY2009 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
-1756000
CY2009 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
7714000
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-11993000
CY2010 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4368000
CY2010 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
-2326000
CY2010 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
11640000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-2537000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
122000
CY2011 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
2058000
CY2011 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
-8083000
CY2011 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
1500000
CY2011 rxii Cash Contributions To Parent Company
CashContributionsToParentCompany
369000
CY2011 rxii Reclassification Of Derivative Liability Upon Elimination Of Obligation
ReclassificationOfDerivativeLiabilityUponEliminationOfObligation
9249000
CY2011 rxii Net Income Loss Attributable To Predecessor Company
NetIncomeLossAttributableToPredecessorCompany
-7682000
CY2011 rxii Predecessor Adjustments To Additional Paid In Capital Share Based Compensation Requisite Service Period Recognition Value
PredecessorAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue
1987000
CY2013 dei Entity Registrant Name
EntityRegistrantName
RXi Pharmaceuticals Corp
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001533040
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M2D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M5D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0126 pure
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7636 pure
CY2013 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
Stock options granted by the Company to employees generally vest as to 12.5% of the shares on the six-month and first anniversary of the grant date and 25% of the shares at the end of each successive three-year period until fully vested
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10263954 shares
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.16
CY2013 us-gaap Debt Instrument Maturity Date Description
DebtInstrumentMaturityDateDescription
Three months or less
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.05
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6311000
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.88
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.55
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
430003 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.04
CY2013 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.65
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y5M23D
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2000 shares
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <em>Concentrations of Credit Risk</em> &#x2014; Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and short-term investments. The Company maintains cash balances in several accounts with one bank, which at times are in excess of federally insured limits. The Company has established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. The Company&#x2019;s investments are maintained in accordance with the Company&#x2019;s investment policy, which defines allowable investments, specifies credit quality standards and limits the exposure of any single issuer.</p> </div>
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26873992 shares
CY2013 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.033 pure
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <i>Uses of estimates in preparation of financial statements</i> &#x2014; The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</p> </div>
CY2013 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
7.50
CY2013 us-gaap Revenues
Revenues
399000
CY2013 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
24000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
89000
CY2013 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
CY2013 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
9000000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20925000
CY2013 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
18000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29535000
CY2013 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
CY2013 us-gaap Payments Of Capital Distribution
PaymentsOfCapitalDistribution
12000
CY2013 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
2000000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2013 us-gaap Stock Issued1
StockIssued1
CY2013 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
CY2013 us-gaap Revenue From Grants
RevenueFromGrants
399000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-20949000
CY2013 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
12250000
CY2013 us-gaap Interest And Other Income
InterestAndOtherIncome
24000
CY2013 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
CY2013 us-gaap Interest Paid
InterestPaid
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
11125000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-20925000
CY2013 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
CY2013 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
5000
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
434000
CY2013 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
28000
CY2013 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1979000
CY2013 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2013 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15651000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
78000
CY2013 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-3000
CY2013 us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
9000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3697000
CY2013 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
-12000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15667000
CY2013 us-gaap Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
CY2013 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
6000000
CY2013 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
434000
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-11125000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-400000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2000
CY2013 us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
1979000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
99000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6263000
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1028000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-253000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15651000
CY2013 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
7982000
CY2013 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
8610000
CY2013 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-9123000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3093000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17651000
CY2013 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
CY2013 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-2002000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
99000
CY2013 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
28000
CY2013 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
8610000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1979000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
62900
CY2013 us-gaap Other Noncash Expense
OtherNoncashExpense
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2013 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
CY2013 us-gaap Operating Expenses
OperatingExpenses
21348000
CY2013 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2013 rxii Other Significant Noncash Transaction Value Of Parent Company Restricted Stock Units And Common Stock Issued In Lieu Of Cash Bonuses
OtherSignificantNoncashTransactionValueOfParentCompanyRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses
CY2013 rxii Forfeiture Rate For Options Granted To Directors
ForfeitureRateForOptionsGrantedToDirectors
0.00 pure
CY2013 rxii Research And Development Intangibles Purchased From Others
ResearchAndDevelopmentIntangiblesPurchasedFromOthers
12250000
CY2013 rxii Allocation Of Management Expenses
AllocationOfManagementExpenses
CY2013 rxii Loss On Exchange Of Equity Instruments
LossOnExchangeOfEquityInstruments
CY2013 rxii Reclassification Of Derivative Liability Upon Elimination Of Obligation
ReclassificationOfDerivativeLiabilityUponEliminationOfObligation
CY2013 rxii Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrants
FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants
CY2013 rxii Operating Loss Carryforwards Expiration Year
OperatingLossCarryforwardsExpirationYear
2033
CY2013 rxii Forfeiture Rate For Options Granted To Employees
ForfeitureRateForOptionsGrantedToEmployees
0.050 pure
CY2013 rxii Preferred Stock Beneficial Conversion Feature
PreferredStockBeneficialConversionFeature
CY2013 rxii Stock Issued During Period Shares Issued For Exchange Of Patent And Technology Rights
StockIssuedDuringPeriodSharesIssuedForExchangeOfPatentAndTechnologyRights
1394997 shares
CY2013 rxii Value Of Parent Company Restricted Stock Units Issued In Lieu Of Bonuses Included In Accrued Expenses
ValueOfParentCompanyRestrictedStockUnitsIssuedInLieuOfBonusesIncludedInAccruedExpenses
CY2013 rxii Fair Value Of Parent Company Stock Options Modified
FairValueOfParentCompanyStockOptionsModified
CY2013 rxii Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Percentage On Completion Of First And Second Eligible Service Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageOnCompletionOfFirstAndSecondEligibleServicePeriod
0.125 pure
CY2013 rxii Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Percentage For Remaining Subsequent Eligible Service Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageForRemainingSubsequentEligibleServicePeriod
0.25 pure
CY2013 rxii Parent Issuance Of Stock And Warrants For Services Or Claims
ParentIssuanceOfStockAndWarrantsForServicesOrClaims
CY2013 rxii Parent Research And Development Intangibles Purchased From Others
ParentResearchAndDevelopmentIntangiblesPurchasedFromOthers
CY2004 us-gaap Net Income Loss
NetIncomeLoss
-3272000
CY2004 rxii Net Transactions With Parent
NetTransactionsWithParent
2393000
CY2008 us-gaap Net Income Loss
NetIncomeLoss
-14373000
CY2008 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3824000
CY2008 rxii Non Cash Equity Adjustments From Parent Company
NonCashEquityAdjustmentsFromParentCompany
750000
CY2008 rxii Cash Contributions From Parent Company
CashContributionsFromParentCompany
7944000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0094 pure
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8870 pure
CY2012 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4573787 shares
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.00
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.10
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5062000
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.62
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2128266 shares
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25840335 shares
CY2012 us-gaap Revenues
Revenues
97000
CY2012 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-30000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
26000
CY2012 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
CY2012 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12880000
CY2012 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
2000
CY2012 us-gaap Preferred Stock Redemption Discount
PreferredStockRedemptionDiscount
9500000
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25695000
CY2012 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
125000
CY2012 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
13000
CY2012 us-gaap Payments Of Capital Distribution
PaymentsOfCapitalDistribution
CY2012 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
CY2012 us-gaap Stock Issued1
StockIssued1
CY2012 us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
CY2012 us-gaap Revenue From Grants
RevenueFromGrants
97000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-12975000
CY2012 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
6173000
CY2012 us-gaap Interest And Other Income
InterestAndOtherIncome
CY2012 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
8000
CY2012 us-gaap Interest Paid
InterestPaid
30000
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2387000
CY2012 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
1000000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-12880000
CY2012 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
CY2012 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
29000
CY2012 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
224000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
968000
CY2012 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
-9500000
CY2012 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
699000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
CY2012 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
13000
CY2012 us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
19000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2621000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9670000
CY2012 us-gaap Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
699000
CY2012 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
CY2012 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
224000
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2387000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-298000
CY2012 us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
597000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
968000
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
147000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4624000
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
223000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
29000
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2012 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
2865000
CY2012 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
3315000
CY2012 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
33000
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-1903000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10451000
CY2012 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2012 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-484000
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
147000
CY2012 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
CY2012 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
12815000
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
968000
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
138000
CY2012 us-gaap Other Noncash Expense
OtherNoncashExpense
CY2012 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2012 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
8500000
CY2012 us-gaap Operating Expenses
OperatingExpenses
13072000
CY2012 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
500000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2012 rxii Other Significant Noncash Transaction Value Of Parent Company Restricted Stock Units And Common Stock Issued In Lieu Of Cash Bonuses
OtherSignificantNoncashTransactionValueOfParentCompanyRestrictedStockUnitsAndCommonStockIssuedInLieuOfCashBonuses
CY2012 rxii Research And Development Intangibles Purchased From Others
ResearchAndDevelopmentIntangiblesPurchasedFromOthers
6173000
CY2012 rxii Allocation Of Management Expenses
AllocationOfManagementExpenses
CY2012 rxii Loss On Exchange Of Equity Instruments
LossOnExchangeOfEquityInstruments
CY2012 rxii Reclassification Of Derivative Liability Upon Elimination Of Obligation
ReclassificationOfDerivativeLiabilityUponEliminationOfObligation
CY2012 rxii Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrants
FairValueOfSharesMandatorilyRedeemableForCashUponExerciseOfWarrants
CY2012 rxii Preferred Stock Beneficial Conversion Feature
PreferredStockBeneficialConversionFeature
9500000
CY2012 rxii Value Of Parent Company Restricted Stock Units Issued In Lieu Of Bonuses Included In Accrued Expenses
ValueOfParentCompanyRestrictedStockUnitsIssuedInLieuOfBonusesIncludedInAccruedExpenses
CY2012 rxii Fair Value Of Parent Company Stock Options Modified
FairValueOfParentCompanyStockOptionsModified
CY2012 rxii Parent Issuance Of Stock And Warrants For Services Or Claims
ParentIssuanceOfStockAndWarrantsForServicesOrClaims
CY2012 rxii Parent Research And Development Intangibles Purchased From Others
ParentResearchAndDevelopmentIntangiblesPurchasedFromOthers

Files In Submission

Name View Source Status
0001193125-14-121519-index-headers.html Edgar Link pending
0001193125-14-121519-index.html Edgar Link pending
0001193125-14-121519.txt Edgar Link pending
0001193125-14-121519-xbrl.zip Edgar Link pending
d667381d10k.htm Edgar Link pending
d667381dex1021.htm Edgar Link pending
d667381dex231.htm Edgar Link pending
d667381dex311.htm Edgar Link pending
d667381dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g667381image1.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxii-20131231.xml Edgar Link completed
rxii-20131231.xsd Edgar Link pending
rxii-20131231_cal.xml Edgar Link unprocessable
rxii-20131231_def.xml Edgar Link unprocessable
rxii-20131231_lab.xml Edgar Link unprocessable
rxii-20131231_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending